drugset / Trial / NCT02678260
Phase I Study of PDR001 in Patients With Advanced Malignancies.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety, tolerability, Pharmacokinetics (PK), and antitumor activity of PDR001 administered intravenous (i.v.) as a single agent to Japanese patients.
Timeline
- Start
- 2016-02-19
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Spartalizumab | Monoclonal antibody | — | Intravenous |